“We are well on our way to achieving our target of 75% access for Yeztugo within 6 months of launch and 90% within 12 months.”

In context

“the end of the second quarter reflected planned inventory build as we expected. While it's still early days, we're extremely pleased with the feedback from both clinicians and consumers as well as the progress of our early discussions with payers and the effectiveness of our launch preparations and execution to date. Notably, the first Yeztugo prescription was written within hours of approval with the first product shipped within 24 hours and the first dose administered within days, well ahead of our expectations. Prior to launch or any commercial engagement, Yeztugo's unaided awareness among healthcare providers was at 72%, more than twice the typical prelaunch awareness with aided awareness at 95%. I look forward to sharing more about Yeztugo's early performance in the coming quarters. We are well on our way to achieving our target of 75% access for Yeztugo within 6 months of launch and 90% within 12 months. Outside the U.S., we have just received a positive CHMP opinion and expect a European Commission decision on lenacapavir in the next 2 months. Our launch preparations in our initial target European territories are underway. Gilead is committed to facilitating access to lenacapavir for those who could benefit from HIV prevention regardless of where they live. With that in mind, we recently announced a partnership with the global fund to bring lenacapavir to approximately 2 million people in primarily low and lower middle-income countries over the next 3 years. We were also pleased that the World Health Organization and the International AIDS Society both recently announced new HIV prevention guidelines recommending the use of lenacapavir. As we look at the rest of 2025 on Slide 11, it's cl”